Five penny that stocks chalked up big gains today

Summary

  • The WCN share price has closed up by 17.6%, as the company announced assay results.
  • QuickFee has seen a remarkable increase in lending activity in Australia.
  • The DRE share price has risen by 8.7% to AU$0.025 in today’s session with a high volume of over 28.9 million shares.

On the last day of the week, the ASX 200 closed the session 0.2% up, at 7080.8 and recovered mostly from Thursday’s fall of 0.48%. Despite today’s gain, the index has closed near the same level since mid-April. The benchmark index is facing tough resistance around 7,100, however, the support around 7,000 is equally strong, keeping the index more or less within this range.

Image Source: Copyright © 2021 Kalkine Media Pty Ltd.

However, this sideways trend is nothing to be worried about if investors look at the right place. Penny socks is the space to explore as it is trending up today, making investors happy. Let’s see which stocks have trended higher during the day:

  1. White Cliff Minerals Limited (ASX:WCN)

The WCN share price closed at AU$0.02, up by 17.6%. However, at the high of the day, the stock was delivering an even higher gain of 47%.

Today, the company provided assay results from its recent rock chip sampling program undertaken at the Cracker Jack project. Gold assay results with up to 37.3 g/t gold have been received from the project, confirming the presence of a narrow but high-grade system.

  1. QuickFee Limited (ASX:QFE)

QuickFee has seen a remarkable increase in lending activity in Australia in the past two months, with March and April being successively the highest lending months in the 2021 financial year. Its US PayNow volume for the month of April 2021 stood at a record US$76.4 million, up 13% over February 2021.

Investors have reacted positively to the record PayNow volume, sending the stock 9.43% higher to AU$0.29 in today’s session.

Read More: QuickFee (ASX:QFE) shares fall despite strong H1 FY2021 results

  1. Noxopharma Limited (ASX:NOX)

Noxopharma has dropped an update on its clinical-stage drug candidate Veyonda® to treat patients with soft tissue sarcomas. The company said that it had appointed a contract research organisation to oversee the study of its the investigational new drug application for Veyonda® in combination with common chemotherapy drug, doxorubicin. This study is being undertaken to provide a proof-of-principle of ability of Veyonda to enhance chemotherapy.

Image Source: ID 1465986 © Drliwa | Megapixl.com

On this positive development, NOX share price has swung up by 18.56% to AU$0.575. A total of 2.2 million shares changed hands today.

Read More: Noxopharm to Commence Veyonda®’s Clinical Trial in COVID-19 Patients in Europe

  1. Dreadnought Resources Limited (ASX:DRE)

The DRE share price has risen by 8.7% to AU$0.025 in today’s session with a high volume of over 28.9 million shares. Significantly, the stock has also marked its new high for 2021.

Yesterday, the company released a presentation with all its business updates. It has an effective exploration strategy in place and maintains a pipeline of strong targets and drill results. The company also shared its 2021 work plan with the shareholders.

  1. PlaySide Studios Limited (ASX:PLY)

The PLY share price has ratcheted up by 8.7% to AU$0.25 as the company has signed a mobile platform games licence agreement with ViacomCBS on behalf of Paramount Pictures Corporation. The agreement has been struck to develop a mobile video game for both Google and Apple’s mobile platforms, based on the feature film ‘The Godfather’.

The licence enables the company for a multi-year global profit-sharing arrangement across Android and iOS devices.

Read More: Playside Studios (ASX:PLY) Soars Up To 75% On ASX Debut


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK